Onychocryptosis, commonly known as an ingrown toenail, is one of the most frequent complaints seen in podiatric and general practice. It occurs when the edge of the nail plate penetrates the surrounding soft tissue, triggering inflammation, pain, infection, and often the formation of hypergranulation tissue. While mild cases respond to conservative measures such as proper nail trimming, warm soaks, and cotton wisp insertion, recurrent or severe cases typically require surgical intervention. Among the surgical options available, chemical matricectomy using phenol has become the most widely practiced technique worldwide due to its high success rate, relative simplicity, and low complication profile.

Understanding the Problem

The nail plate grows from the germinal matrix, a specialized area of tissue beneath the proximal nail fold. When a portion of the nail border digs into the lateral nail fold—often due to improper cutting, tight footwear, trauma, or an inherently curved nail plate—the body responds with an inflammatory reaction. If left untreated, this can progress to chronic infection, abscess formation, and the growth of exuberant granulation tissue that further traps the nail edge, creating a self-perpetuating cycle. Surgical treatment aims to permanently eliminate the offending portion of the nail so it can no longer intrude into the soft tissue.

The Rationale for Chemical Matricectomy

Historically, ingrown toenails were treated with wedge resection procedures, such as the Winograd or Zadik operations, which involve surgically excising a portion of the nail plate along with the corresponding germinal matrix tissue using a scalpel. While effective, these procedures require more extensive dissection, meticulous hemostasis, and often produce more postoperative pain and longer healing times. Phenolization emerged as an alternative that achieves matrix destruction chemically rather than mechanically, avoiding the need to cut and remove matrix tissue directly.

Phenol (carbolic acid) is a caustic, protein-denaturing agent that, when applied directly to matrix tissue, causes controlled chemical cauterization. This destroys the germinal cells responsible for producing the offending portion of the nail, preventing that segment from regrowing. Because the destruction is chemical rather than purely mechanical, the technique can be performed with a smaller incision, less bleeding, and reduced technical difficulty compared to traditional excisional matricectomy.

The Surgical Procedure

The procedure is typically performed under local anesthesia using a digital block, most commonly with plain lidocaine (epinephrine is generally avoided in digital blocks, though modern evidence increasingly supports its cautious use). Once adequate anesthesia is achieved, a pneumatic or rubber tourniquet is often applied at the base of the toe to create a bloodless field, which is essential because phenol’s efficacy can be diminished in the presence of blood.

The offending lateral or medial border of the nail plate—or in severe bilateral cases, the entire nail—is then avulsed, meaning it is separated and removed from the nail bed and matrix using a nail elevator and English anvil nail splitters. This exposes the germinal matrix at the base of the nail fold.

A cotton-tipped applicator or small pledget soaked in 88% phenol solution is then applied directly to the exposed matrix tissue, typically for one to three applications lasting approximately thirty seconds to one minute each, with cleaning between applications using isopropyl alcohol or saline to remove the coagulated, whitened tissue produced by the phenol. The alcohol also helps neutralize residual phenol, reducing the risk of excessive tissue damage to surrounding structures. The tourniquet is then released, hemostasis is confirmed, and the toe is dressed with an antiseptic, non-adherent dressing.

Postoperative Care and Recovery

Patients are generally advised to keep the foot elevated and dry for the first twenty-four to forty-eight hours, after which daily dressing changes with antiseptic soaks are recommended until the wound has fully granulated and epithelialized, a process that typically takes three to six weeks. Unlike excisional techniques that involve sutured wounds, phenol matricectomy leaves an open wound that heals by secondary intention. Patients often experience a moderate, malodorous discharge during the healing phase, which is a normal consequence of the chemical cauterization and tissue sloughing rather than necessarily a sign of infection, though this can occasionally be alarming if patients are not properly counseled beforehand.

Efficacy and Complications

Numerous clinical studies and systematic reviews have demonstrated that phenol matricectomy achieves recurrence rates generally in the range of 1 to 8 percent, which compares favorably to, or exceeds, the outcomes of traditional excisional surgery. The technique is particularly valued for its reproducibility even among less experienced surgeons, since the depth and extent of matrix destruction is somewhat self-limiting due to the chemical properties of phenol, unlike a scalpel, which requires precise anatomical knowledge to avoid leaving residual matrix tissue.

Complications, while relatively uncommon, can include prolonged drainage, delayed wound healing, postoperative infection, and rarely, thermal or chemical injury to adjacent tissue if phenol is not carefully controlled. This is called a phenol burn. Some patients also report temporary hypopigmentation of the treated nail fold skin, particularly in individuals with darker skin tones, due to phenol’s cytotoxic effect on melanocytes. Diabetic patients and those with peripheral vascular disease require careful case selection, as impaired healing capacity may increase the risk of complications in this population.

Advantages Over Alternative Techniques

Beyond its strong success rates, phenolization offers several practical advantages. It requires minimal surgical instrumentation, avoids the need for suturing, and generally results in less intraoperative bleeding than excisional approaches. The procedure can typically be completed in fifteen to twenty minutes in an outpatient or office setting, making it highly accessible and cost-effective. Patient satisfaction tends to be high, given the relatively quick return to normal activity and footwear compared to more invasive surgical alternatives.

Phenol matricectomy has become the gold standard for definitive surgical management of recurrent or severe ingrown toenails. By chemically ablating the germinal matrix responsible for producing the offending nail border, the technique offers a minimally invasive, technically reproducible, and highly effective solution with low recurrence rates. While it requires patient tolerance of a longer secondary-intention healing process and careful postoperative wound care, its overall safety profile and consistent outcomes have cemented its place as a preferred approach in modern podiatric and dermatologic surgical practice.

Among the many conditions that affect the feet, the pincer toenail—also known as an involuted nail, trumpet nail, or omega nail—stands out as one of the more painful and misunderstood nail deformities. Unlike the more familiar ingrown toenail, which typically results from improper trimming or trauma, the pincer nail is a structural deformity of the nail plate itself. It develops gradually, often over years, and can cause significant discomfort, difficulty wearing shoes, and even secondary infections if left untreated. Understanding what causes this condition, how it is diagnosed, and what treatment options exist is essential for anyone experiencing persistent toe pain that does not resolve with typical home remedies.

What Is a Pincer Toenail?

A pincer toenail is defined by an excessive transverse curvature of the nail plate, meaning the nail curls inward from both sides as it grows toward the tip of the toe. In severe cases, the two edges of the nail can curve so dramatically that they nearly touch or even overlap beneath the nail, forming a shape reminiscent of a pincer, trumpet, or the Greek letter omega—hence its various names. This is distinct from a simple ingrown nail, in which only one edge of an otherwise flat nail digs into the surrounding skin. In pincer nails, the entire nail plate is deformed, and the curling increases progressively from the base (proximal end) to the tip (distal end) of the nail.

The condition most commonly affects the big toe, though it can occur on any toe and, in rare cases, bilaterally on corresponding toes of both feet. As the nail curves inward, it compresses the soft tissue of the nail bed and the lateral nail folds—the skin on either side of the nail—leading to pain, inflammation, and sometimes granulation tissue or drainage.

Causes and Contributing Factors

The exact cause of pincer nail deformity is not always clear, and it is generally considered multifactorial. Several contributing factors have been identified:

Genetics and heredity play a role in many cases, with some individuals inheriting a predisposition toward abnormally curved nail plates. Trauma to the nail matrix—the tissue at the base of the nail responsible for producing new nail material—can alter the shape of nail growth going forward. This trauma might result from a single significant injury, such as dropping a heavy object on the toe, or from repetitive microtrauma caused by tight or poorly fitting footwear, particularly shoes with narrow toe boxes.

Underlying bone abnormalities are another important factor. Conditions such as osteoarthritis, bone spurs, or changes in the shape of the underlying toe bone (the distal phalanx) can push upward against the nail bed, encouraging the nail to curl around it. This is particularly common in older adults, where age-related bone remodeling can subtly reshape the toe.

Systemic conditions have also been linked to pincer nail development, including certain medications (notably some beta-blockers), psoriasis, and connective tissue disorders. Additionally, poor circulation, fungal nail infections (onychomycosis), and repetitive pressure from certain occupations or activities—such as running or ballet—can contribute to or worsen the deformity.

Symptoms

The hallmark symptom of a pincer toenail is pain, particularly at the tip of the toe where the curled edges of the nail dig into the surrounding soft tissue. This pain often worsens with pressure, such as when wearing closed-toe shoes or during physical activity. Over time, the affected area may become red, swollen, and tender to the touch. In more advanced cases, the pressure and irritation can lead to the formation of granulation tissue (excess, fragile tissue that bleeds easily), localized infection, or a chronic wound that fails to heal properly. Some patients also report an aching sensation deep within the toe, distinct from the surface-level tenderness typically associated with ingrown nails.

Diagnosis

Diagnosis of a pincer nail is typically made through clinical examination by a podiatrist or dermatologist. The characteristic transverse curvature is usually visible on inspection, and the clinician will assess the degree of curvature, the condition of the surrounding skin, and any signs of infection. In some cases, imaging such as an X-ray may be used to evaluate the underlying bone and rule out or confirm bony abnormalities like exostoses (bone spurs) that could be contributing to the deformity. This is particularly important when planning surgical treatment, as addressing an underlying bone spur may be necessary to prevent recurrence.

Treatment Options

Treatment for pincer toenails ranges from conservative management to surgical intervention, depending on the severity of the deformity and the degree of associated pain or complications.

Conservative approaches are often tried first, especially in mild cases. These include wearing wider, more accommodating footwear to reduce pressure on the toe, using padding or nail braces designed to gradually flatten the nail’s curvature, and careful nail trimming performed by a professional to avoid worsening the ingrowth. Nail bracing, in particular, has gained popularity as a non-invasive method; a small, flexible brace or wire is applied to the nail surface to apply gentle corrective tension over time, gradually reshaping the nail plate as it grows.

Medical treatments may be used to manage associated infection or inflammation, including topical or oral antibiotics if infection is present, and anti-inflammatory measures to reduce swelling and pain.

Surgical treatment is often necessary for moderate to severe cases, or when conservative measures fail to provide relief. The most common surgical approach involves partial or total nail avulsion (removal of the nail) combined with matrixectomy, a procedure that destroys a portion of the nail matrix—often chemically with phenol, or surgically—to permanently narrow the nail and prevent the deformity from recurring. In cases where an underlying bone spur is contributing to the problem, the surgeon may also perform a bone resection to remove the offending prominence, addressing the root cause rather than just the nail itself.

The pincer toenail, though less widely recognized than the common ingrown toenail, represents a distinct and often more complex deformity requiring careful evaluation and, frequently, professional treatment. Its causes are varied, spanning genetic predisposition, trauma, underlying bone changes, and systemic health factors, which means effective treatment often requires addressing more than just the visible symptoms. For those experiencing persistent toe pain, particularly pain that worsens with pressure and is accompanied by visible nail curvature, consultation with a podiatrist is strongly recommended. Early intervention—whether through conservative bracing or surgical correction—can prevent the progression of the deformity, alleviate chronic discomfort, and reduce the risk of secondary infection, ultimately restoring comfort and normal function to the affected foot.

Psoriasis is often thought of as a skin condition that shows up on the elbows, knees, or scalp, but for many people it also takes hold in a far more inconvenient and painful location: the feet. Because the feet bear the body’s weight, absorb constant friction, and are enclosed in shoes for much of the day, psoriasis in this region creates a unique set of physical, functional, and emotional challenges that differ from psoriasis elsewhere on the body.

What Psoriasis Looks Like on the Feet

Psoriasis is an autoimmune condition in which the immune system mistakenly accelerates the growth cycle of skin cells. Instead of shedding over the course of a month, skin cells are produced and pushed to the surface in a matter of days, causing them to pile up into thick, scaly patches. On most parts of the body, this results in the raised, red plaques covered with silvery scale that are the hallmark of plaque psoriasis. On the feet, however, the condition can take several distinct forms.

The most common variant affecting the feet is plaque psoriasis on the soles, which produces thickened, cracked, and often painful patches of skin on the heel or ball of the foot. A related but more severe form is palmoplantar psoriasis, which specifically targets the palms of the hands and soles of the feet. Because the skin on the soles is naturally thicker, plaques here tend to be more resistant to treatment and more prone to painful fissures, or cracks, that can bleed and become infected.

Another form, palmoplantar pustulosis, causes small, fluid-filled pustules to form within red, inflamed skin on the soles. These pustules eventually dry into brown, scaly spots. Though not caused by infection, the appearance can be alarming, and the condition is frequently painful enough to make walking difficult.

Psoriasis can also affect the toenails, a condition called psoriatic nail disease. This may cause pitting, discoloration, thickening, or crumbling of the nails, and in severe cases the nail can separate from the nail bed entirely, a condition known as onycholysis. Nail involvement often signals a higher likelihood of psoriatic arthritis, an inflammatory joint condition that frequently accompanies psoriasis.

Physical and Functional Impact

The feet are not a passive body part; they are the foundation for nearly every form of movement, and this is precisely what makes psoriasis in this location so disruptive. Thickened, cracked plaques on the sole can turn something as simple as standing or walking into a painful ordeal. Deep fissures in the skin, particularly around the heel, can split open with each step, leading to bleeding, stinging pain, and a heightened risk of bacterial infection.

Footwear compounds the problem. Shoes create a warm, often sweaty environment that can aggravate inflamed skin, while the friction and pressure of walking can worsen plaques or trigger new ones through a phenomenon called the Koebner response, in which skin trauma provokes psoriasis to appear at the site of injury. Many people with foot psoriasis find that they need looser, softer, or custom-fitted shoes to avoid further irritation, and some struggle to find footwear that is both comfortable and presentable for work or social settings.

When psoriatic arthritis is also present, the joints of the feet and ankles can become swollen, stiff, and painful, and the connective tissue where tendons attach to bone, such as the Achilles tendon or plantar fascia, can become inflamed. This combination of skin and joint involvement can significantly limit mobility, making stairs, prolonged standing, or athletic activity difficult or impossible during flare-ups.

Emotional and Social Consequences

Because the feet are often on display in warmer months or in social settings such as swimming pools, gyms, or nail salons, visible psoriasis can be a source of significant self-consciousness. Many people avoid sandals, going barefoot, or activities that expose their feet, which can lead to social withdrawal or anxiety. There is also a persistent, though inaccurate, public perception that skin conditions like psoriasis are contagious, which can lead to uncomfortable questions or stares.

The chronic pain associated with foot psoriasis can additionally affect mental health more broadly. Difficulty walking or standing can interfere with work, especially in jobs that require being on one’s feet for long periods, and can limit participation in exercise or hobbies. Research has consistently linked psoriasis, and palmoplantar forms in particular, with higher rates of anxiety and depression, likely driven by this combination of physical discomfort, visible symptoms, and lifestyle limitations.

Managing Foot Psoriasis

Treatment for foot psoriasis generally mirrors treatment for psoriasis elsewhere but often requires more intensive or combined approaches because the thick skin of the soles is harder to penetrate with topical medications. Dermatologists commonly recommend topical corticosteroids, vitamin D analogues, or retinoids, sometimes applied under occlusion (covered with a bandage or plastic wrap overnight) to improve absorption. Moisturizing regularly is essential to prevent the painful cracking that comes with dry, thickened skin.

For more severe or resistant cases, phototherapy, oral medications, or biologic drugs that target specific parts of the immune system may be used. Biologics in particular have improved outcomes for many people with palmoplantar psoriasis, a form that historically responded poorly to topical treatment alone.

Practical daily measures also matter. Choosing well-cushioned, breathable footwear, using moisture-wicking socks, avoiding harsh soaps, and gently exfoliating thickened skin can all reduce discomfort. Podiatric care becomes especially important for people with cracked heels or nail involvement, as proper foot care can prevent secondary infections that would otherwise complicate treatment.

Psoriasis on the feet is more than a cosmetic concern. It combines physical pain, functional limitation, and emotional strain in a part of the body that is essential to daily life. Understanding the different forms it can take, from plaque psoriasis and pustulosis to nail disease and associated arthritis, helps explain why this presentation of the condition often requires more aggressive and individualized treatment. With appropriate medical care, thoughtful footwear choices, and consistent skin care, many people are able to manage their symptoms and maintain the mobility and comfort that healthy feet make possible.

Pitted keratolysis is a superficial bacterial skin condition that primarily affects the soles of the feet, though it can occasionally appear on the palms. It is characterized by small, crater-like pits in the thickened skin of the foot, accompanied by a distinctive and often pungent odor. While the condition is not dangerous and rarely causes serious medical complications, it can be a source of significant embarrassment and discomfort for those affected, particularly athletes, military personnel, and anyone whose feet are regularly exposed to warm, damp conditions. Understanding the treatment of pitted keratolysis requires first understanding its cause, since effective management depends on addressing both the bacterial infection itself and the environmental conditions that allow it to flourish.

Understanding the Underlying Cause

Pitted keratolysis, also known as ringed keratolysis, is caused by a range of bacterial species, with the most common culprits being Corynebacteria, Dermatophilus congolensis, Kytococcus sedentarius, Actinomyces, and Streptomyces. These bacteria are not inherently dangerous; they are often present on the skin in small numbers without causing any problems. The trouble begins when feet are kept in warm, moist conditions for extended periods, such as inside sweaty socks and shoes, or in occlusive footwear like boots or rubber-soled work shoes. Bacteria thrive under moist and warm conditions, and in this environment they multiply rapidly, producing enzymes that break down keratin, the structural protein that makes up the outer layer of skin. This breakdown of keratin is what produces the characteristic pits, and the bacterial byproducts are responsible for the foul smell that often accompanies the condition.

Because the appearance of pitted keratolysis is so distinctive, diagnosis is typically made through visual examination alone, without the need for laboratory testing. A clinician may, however, choose to take a skin scraping or swab if the diagnosis is uncertain or if other conditions, such as fungal infections, need to be ruled out.

Topical Antibiotic Therapy

The cornerstone of treatment for pitted keratolysis is topical antibiotic therapy aimed at eliminating the causative bacteria. Topical antibiotics are typically prescribed in a lotion form that is rubbed directly onto the affected skin, with common choices including clindamycin, erythromycin, and fusidic acid. These medications work by killing or inhibiting the growth of the bacteria responsible for the keratin breakdown, allowing the skin to heal and the odor to resolve.

Clindamycin in particular has been highlighted as effective against the Corynebacteria species frequently implicated in this condition. One notable development in treatment has been the combination of clindamycin with benzoyl peroxide in a single topical gel, which was studied as a novel therapeutic approach and found to be effective in clearing the infection while also providing antiseptic benefit. Mupirocin is sometimes reserved for cases involving bacterial strains that prove resistant to first-line agents. Most treatment courses involve applying the chosen antibiotic once or twice daily for a period of two to four weeks, though the exact duration can vary depending on the severity of the infection and the individual’s response to treatment.

In addition to prescription antibiotics, topical antiseptics such as benzoyl peroxide washes or gels are frequently used either alongside antibiotics or as an adjunct therapy. These agents help reduce the overall bacterial load on the skin and can shorten the time needed for symptoms to resolve.

Managing Moisture and Hyperhidrosis

Because excessive sweating, or hyperhidrosis, is the primary environmental driver of pitted keratolysis, controlling moisture is just as important as eliminating the bacteria themselves. Without addressing the underlying dampness, even a successful course of antibiotics may not prevent the condition from recurring.

Aluminum chloride-based antiperspirants are commonly recommended for this purpose. In some cases, reducing associated hyperhidrosis with the application of a roll-on antiperspirant, such as a 20% aluminum chloride solution, may be helpful in managing the condition. These products are applied to the soles of the feet, much as one would apply antiperspirant to the underarms, and work by temporarily blocking sweat glands.

For patients with more severe or treatment-resistant hyperhidrosis, more advanced interventions exist. Botulinum toxin injections, for example, have been used to treat plantar hyperhidrosis in conjunction with pitted keratolysis, reducing sweat production at the source and thereby removing the moist environment the bacteria need to thrive. While not a first-line treatment, this option may be considered for individuals whose sweating is severe enough to make standard treatments insufficient.

Hygiene and Lifestyle Modifications

Alongside medical treatment, a range of hygiene and lifestyle changes play a critical supporting role in both treating active infections and preventing recurrence. Patients are generally advised to wash their feet daily with antibacterial soap and to dry them thoroughly, paying particular attention to the spaces between the toes where moisture tends to linger.

Sock and footwear choices matter considerably. Moisture-wicking socks, particularly those made of wool rather than cotton, help draw sweat away from the skin rather than trapping it against the foot. Socks should be changed frequently throughout the day to prevent excessive moisture buildup, and one study recommended washing socks at a temperature of 60 degrees Celsius to kill any bacteria that may have transferred from the skin onto the fabric. Interestingly, research into sock materials has continued to evolve; a double-blind randomized controlled trial found that socks coated with zinc oxide nanoparticles were more effective than uncoated socks at reducing the development of pitted keratolysis and minimizing the associated odor.

Footwear itself should be chosen with breathability in mind, favoring shoes made from natural or moisture-permeable materials over tightly sealed synthetic options. Rotating dry insoles on a daily basis ensures that feet are never standing on persistently damp shoe interiors, and patients are typically advised to avoid sharing footwear with others to limit bacterial transmission.

Prognosis and Follow-Up

The good news for those affected by pitted keratolysis is that the condition responds well to appropriate treatment in the vast majority of cases. Pitted keratolysis can be treated successfully with adequate foot hygiene, topical antibiotics, and antiseptics, often resolving within a matter of weeks once treatment begins. However, because the underlying environmental triggers, namely sweat and occlusive footwear, are often a persistent part of a person’s lifestyle or occupation, recurrence is common if preventive habits are not maintained long-term.

For this reason, clinicians often emphasize that successful treatment is really a two-part process: clearing the active infection with antibiotics and antiseptics, and then maintaining the hygiene and moisture-control habits needed to prevent the bacteria from re-establishing themselves. Patients whose symptoms do not improve with standard therapy are generally advised to return for follow-up, as resistant cases may require alternative antibiotic regimens or additional interventions targeting hyperhidrosis.

Pitted keratolysis, while harmless in a medical sense, can meaningfully affect a person’s comfort and confidence. Effective treatment rests on three pillars: topical antibiotics to eliminate the causative bacteria, antiperspirant or other moisture-control measures to address the hyperhidrosis that allows the infection to take hold, and consistent foot hygiene practices to prevent recurrence. With this combined approach, most people can expect their symptoms to clear within weeks, provided they also commit to the lifestyle adjustments needed to keep their feet dry over the longer term.

Onychauxis is a common nail pathology characterised by a uniform thickening and hypertrophy of the nail plate, typically without significant structural deformity or lateral deviation. Often confused with onychogryphosis — a more severe condition involving pronounced curvature and distortion — onychauxis presents as a straightforward, though clinically significant, overgrowth of the nail. It most frequently affects the toenails, particularly the hallux (great toe), and is encountered regularly in podiatric practice. While the condition is not inherently dangerous, untreated onychauxis can lead to pain, subungual pressure, secondary infection, and considerable reduction in quality of life, particularly in elderly or immunocompromised populations. Understanding the aetiology, clinical presentation, and range of treatment options is essential for effective podiatric management.

Aetiology and Predisposing Factors

Onychauxis arises from a disruption in the normal mitotic activity of the nail matrix, which results in accelerated or abnormal nail cell production. This can be triggered by a variety of intrinsic and extrinsic factors. Repeated microtrauma — commonly caused by poorly fitting footwear, athletic activity, or prolonged pressure on the nail — is among the most frequent causes. The nail matrix, responding to chronic insult, overproduces keratinocytes, leading to progressive thickening of the nail plate over time.

Systemic conditions also play a significant aetiological role. Peripheral vascular disease, diabetes mellitus, and other conditions associated with poor circulation impair normal nail growth and repair mechanisms. Psoriasis is a notable dermatological cause, as it can affect the matrix and nail bed, producing thickened, dystrophic nails. Fungal infections, particularly onychomycosis caused by dermatophytes, are a major contributor to nail hypertrophy and must be differentiated from — or identified as co-existing with — onychauxis prior to formulating a treatment plan. Age-related changes in nail growth, circulation, and tissue elasticity mean that onychauxis is particularly prevalent in older adults.

Clinical Presentation and Assessment

Clinically, onychauxis presents as a uniformly thickened nail plate, often with a yellow, brown, or opaque discolouration. The nail surface may appear smooth or slightly ridged, and the nail is denser and harder than normal. Unlike onychogryphosis, the nail does not typically deviate laterally or assume a ram’s horn appearance. Patients may report difficulty cutting their nails, discomfort when wearing closed footwear, and occasionally pain at the nail margins due to pressure on the surrounding soft tissue.

A thorough clinical assessment is essential before initiating treatment. The clinician should evaluate neurovascular status, particularly in patients with diabetes or peripheral arterial disease, as compromised circulation affects healing and increases infection risk. The presence of fungal infection should be considered, and nail specimens may be sent for mycological analysis where onychomycosis is suspected. Assessment of footwear is also important, as ongoing mechanical trauma will undermine any intervention.

Conservative Treatment

The primary and most commonly employed treatment for onychauxis is conservative reduction of the nail plate through mechanical debridement. This is typically performed by a podiatrist using an electric burr or nail drill, which safely reduces the thickness of the nail without trauma to the underlying nail bed. The procedure is painless when performed correctly and results in immediate patient comfort. Following reduction, the nail is filed smooth to minimise pressure and friction within footwear.

Regular professional nail care is often necessary on an ongoing basis, as onychauxis tends to recur without addressing its underlying cause. Patients with systemic conditions or poor manual dexterity — particularly the elderly — benefit from scheduled podiatric appointments every six to ten weeks for maintenance.

Emollient therapy forms an important adjunct to mechanical reduction. Regular application of urea-based creams (typically 10–40% concentration) to the nail and surrounding tissue softens the nail plate, improves pliability, and facilitates easier debridement at subsequent appointments. Urea is keratolytic and helps to gradually reduce nail thickness when used consistently. Patient education around the daily application of emollients is an important component of a conservative management programme.

Footwear advice and orthotic intervention are valuable adjuncts. Patients should be guided towards footwear with a wide, deep toe box that reduces direct pressure on the nail. In cases where structural foot deformities — such as hallux valgus or digital contractures — contribute to nail trauma, orthotic devices or toe props may offload pressure and help prevent recurrence.

Treatment of Underlying Causes

Where onychomycosis is identified as a contributing or causative factor, antifungal therapy is indicated. Topical antifungals, such as amorolfine lacquer or ciclopirox, may be effective in mild to moderate cases, though their penetration of a thickened nail plate is limited. Systemic antifungals — most commonly terbinafine — are more effective for established fungal nail infection and are typically prescribed for twelve weeks for toenail involvement. Clinicians must assess suitability based on the patient’s medical history, medications, and liver function before initiating systemic therapy.

In patients with psoriatic nail disease, treatment of the underlying psoriasis — through topical corticosteroids, intralesional injections, or systemic biologics where indicated — may improve nail appearance and reduce hypertrophy. Dermatological referral may be appropriate in complex cases.

Surgical and Chemical Avulsion

In cases where onychauxis causes significant ongoing pain, recurring infections, or where conservative measures fail to provide adequate relief, more definitive intervention may be considered. Nail avulsion — either partial or total — involves the removal of the thickened nail plate under local anaesthesia. This provides immediate relief and allows inspection of the underlying nail bed for pathology.

Chemical matrixectomy using phenol (typically an 80–88% solution) is frequently performed following avulsion to permanently ablate all or part of the nail matrix, preventing regrowth. This is particularly appropriate when the nail is severely thickened, the patient cannot tolerate recurrent debridement, or where the nail serves no functional purpose. The procedure is well-tolerated and has a high success rate, though it requires careful wound management in the postoperative period, especially in patients with vascular compromise or diabetes.

Surgical excision of the nail matrix is an alternative to chemical ablation but is less commonly performed in routine podiatric practice due to its greater invasiveness and the adequacy of phenolisation in most cases.

Onychauxis, though a benign nail condition, warrants careful assessment and appropriate management to prevent pain, infection, and functional impairment. The cornerstone of treatment remains conservative debridement by a trained podiatrist, supported by emollient therapy, footwear advice, and management of any underlying systemic or dermatological conditions. In refractory or severely symptomatic cases, chemical matrixectomy offers a definitive and effective solution. A patient-centred, holistic approach — considering the individual’s overall health status, lifestyle, and goals — is essential to achieving the best outcomes in the treatment of this common foot condition.

Nails are far more than cosmetic features. As keratinised appendages of the skin, they serve protective and sensory functions, and — perhaps most importantly from a clinical standpoint — they act as visible indicators of systemic health. Among the many nail disorders that dermatologists and clinicians encounter, onychorrhexis stands out for both its prevalence and the breadth of conditions it can signal. Characterised by longitudinal ridging and brittleness that often leads to splitting or breaking of the nail plate, onychorrhexis is a condition worth understanding in depth: its causes, its presentation, its implications, and its management.

Defining Onychorrhexis

The term “onychorrhexis” derives from the Greek words onyx (nail) and rhexis (rupture or fracture). It describes a distinctive nail abnormality in which parallel ridges run lengthwise along the nail plate, from the base toward the free edge. These ridges are frequently accompanied by increased fragility, causing the nail to split longitudinally or flake at the tip. The condition affects fingernails more commonly than toenails and can occur in both males and females, though it is somewhat more prevalent among older adults and women — two groups whose nails may be subjected to different hormonal influences and environmental stresses.

It is worth distinguishing onychorrhexis from a related but separate condition: onychoschizia, in which the nail splits horizontally into layers at the free edge. While both conditions involve nail brittleness and are sometimes grouped together under the broader category of “brittle nails,” their underlying mechanisms and typical causes can differ. Onychorrhexis involves structural disruption running the full length of the nail, suggesting a deeper disruption to nail plate formation at the matrix level.

The Structure of the Nail and How It Goes Wrong

To understand onychorrhexis, one must first appreciate normal nail architecture. The nail plate is composed of densely compacted, dead keratinised cells produced by the nail matrix — the tissue tucked beneath the proximal nail fold. These cells are arranged in horizontal layers and are bound together by intercellular lipids and structural proteins. A healthy nail plate is smooth, resilient, semi-translucent, and firmly adherent to the nail bed beneath it.

When nail matrix function is disrupted — whether by nutritional deficiency, systemic disease, physical trauma, or chemical insult — the orderly production of nail cells is disturbed. The result is a nail plate with structural weaknesses running in the direction of growth: the classic longitudinal ridges of onychorrhexis. These ridges represent lines of reduced cohesion within the nail, and the brittleness arises because the compromised intercellular bonding cannot withstand the mechanical stresses of daily life.

Causes and Risk Factors

The aetiology of onychorrhexis is multifactorial and can be broadly divided into systemic, nutritional, environmental, and local causes.

Among systemic causes, thyroid disorders — particularly hypothyroidism — are among the most frequently implicated. The thyroid hormones play an important role in regulating the growth and differentiation of epithelial cells, including those of the nail matrix. When thyroid function is impaired, nail growth slows and the structural integrity of the nail plate deteriorates. Other endocrine conditions, including hypoparathyroidism and peripheral vascular disease, can similarly compromise nail health.

Nutritional deficiencies are another significant contributor. Iron deficiency is particularly well documented; the nails depend on adequate iron-carrying haemoglobin for their oxygen supply, and when iron stores are depleted, both nail growth and quality suffer. Deficiencies in biotin (vitamin B7), zinc, protein, and essential fatty acids have also been associated with brittle, ridged nails. This connection explains why onychorrhexis is not uncommon in individuals with eating disorders, malabsorptive conditions such as coeliac disease or inflammatory bowel disease, or those following very restrictive diets.

Environmental and chemical factors account for a substantial proportion of cases, particularly among people whose hands are frequently immersed in water or exposed to harsh chemicals. Repeated wetting and drying of the nails causes the nail plate to expand and contract cyclically, weakening its structural integrity over time. Acetone-based nail polish removers, household detergents, and industrial solvents strip the nail of its natural lipid content, leaving it dry and prone to ridging and fracture. This is why onychorrhexis is so common among healthcare workers, cleaners, hairdressers, and others in occupations involving regular hand washing or chemical exposure.

Aging is itself a risk factor. As people grow older, nail growth slows and the water and lipid content of the nail plate naturally decreases, rendering it drier and more brittle. Longitudinal ridging in older adults is so common that mild onychorrhexis is often considered a normal variant of aging rather than a pathological finding.

Dermatological conditions including lichen planus, alopecia areata, and psoriasis can also produce nail changes consistent with onychorrhexis, typically through their inflammatory effects on the nail matrix. Certain medications — particularly retinoids used in the treatment of acne and psoriasis — are known to cause nail brittleness as a side effect.

Diagnosis and Clinical Evaluation

Onychorrhexis is primarily a clinical diagnosis, made on the basis of the characteristic appearance of the nails. However, because the condition can signal underlying systemic disease, a thorough evaluation is warranted when the cause is not immediately apparent. A clinician will typically take a detailed history, asking about occupation, diet, medication use, family history, and the presence of other symptoms that might point toward thyroid dysfunction, anaemia, or connective tissue disease.

Laboratory investigations may include a full blood count, thyroid function tests, serum ferritin, zinc, and albumin levels. In some cases, a biopsy of the nail matrix or nail fold may be indicated to exclude inflammatory dermatoses. Dermoscopy — the use of a handheld magnifying instrument — can assist in characterising the ridging pattern and identifying features that might suggest a specific underlying diagnosis.

Management and Treatment

Treatment of onychorrhexis is guided by its underlying cause. When a systemic condition or nutritional deficiency is identified, addressing that root cause often leads to gradual improvement in nail quality over several months — the timescale reflecting the slow growth of the nail plate (approximately three to four millimetres per month for fingernails).

For cases related to environmental exposure, protective measures are the cornerstone of management. Wearing cotton-lined gloves during wet work, reducing the frequency of nail polish remover use, and applying nail-specific moisturisers or cuticle oils can all help to restore the nail’s lipid content and reduce brittleness. Nail hardeners containing formaldehyde, paradoxically, can worsen brittleness with prolonged use and should be approached with caution.

Biotin supplementation has attracted considerable interest as a treatment for brittle nails, and several small studies have reported improvements in nail thickness and hardness. While the evidence base remains modest, biotin is generally safe and is often recommended in cases where no specific deficiency has been identified. Adequate protein and overall balanced nutrition provide the foundational building blocks for healthy nail production.

Onychorrhexis, though often dismissed as a minor cosmetic inconvenience, deserves thoughtful attention. It is a condition at the intersection of dermatology, internal medicine, and lifestyle, capable of reflecting everything from dietary gaps to thyroid disease to the cumulative toll of occupational chemical exposure. By recognising its characteristic appearance, understanding the diverse factors that contribute to it, and pursuing both systemic and topical treatments tailored to its cause, clinicians and patients alike can address not only the visible signs in the nail but the underlying conditions they represent. In this sense, the humble nail ridge carries a message well worth reading.

Onychophosis is a dermatological condition affecting the toenails, characterised by the hyperkeratotic accumulation of callus tissue within the nail grooves — the lateral and proximal sulci that border the nail plate. Though frequently overlooked or mistaken for other nail pathologies such as onychocryptosis (ingrown toenail) or subungual hyperkeratosis, onychophosis represents a distinct clinical entity that demands targeted management. The condition can cause significant discomfort, particularly in elderly or diabetic populations, and when left untreated, may progress to ulceration, infection, or impaired mobility. Understanding its causes, clinical presentation, and the range of available treatments is essential for effective podiatric care.

Understanding the Condition

The term onychophosis derives from the Greek words for nail (onyx) and callus (phosis), reflecting its defining feature: a localised build-up of hyperkeratotic tissue. This overgrowth occurs primarily in response to chronic mechanical pressure and friction between the nail plate and the surrounding soft tissue of the nail groove. Ill-fitting footwear is among the most common precipitating factors, as narrow toe boxes or excessive pressure from socks and hosiery concentrate force along the nail borders. Biomechanical abnormalities, including hallux valgus, hammer toe deformities, and altered gait patterns, further predispose individuals to this condition by redirecting pressure onto vulnerable nail sulci.

The great toe is most commonly affected, though any digit may develop onychophosis. Patients typically present with pain or tenderness along the nail groove, a sensation of pressure under or beside the nail, and visible thickening of the periungual skin. In severe or long-standing cases, the hyperkeratotic tissue may become macerated, fissured, or secondarily infected, introducing a risk of cellulitis or deeper soft tissue complications, particularly in those with diabetes mellitus or peripheral vascular disease.

Conservative Treatment Approaches

The cornerstone of onychophosis management is conservative, non-surgical debridement, which aims to remove the accumulated keratinous tissue and relieve pressure. This procedure is typically performed by a trained podiatrist using a scalpel, curette, or nail rasp. The practitioner carefully removes the hyperkeratotic material from within the nail sulcus without disrupting the nail matrix or surrounding healthy tissue. Regular debridement — often every six to twelve weeks depending on the rate of recurrence — is effective in managing symptoms and preventing progression for most patients.

Alongside debridement, podiatrists frequently apply emollients and keratolytic agents to soften the thickened tissue and reduce the likelihood of rapid regrowth. Preparations containing urea (typically in concentrations of 10–40%), salicylic acid, or lactic acid are commonly employed. These agents work by disrupting the protein bonds within the keratinised tissue, making it more pliable and amenable to mechanical removal. Patients are often instructed to apply these preparations at home between clinical appointments to maintain tissue suppleness and extend the interval between treatments.

Nail care and patient education are critical adjuncts to clinical treatment. Appropriate nail-cutting technique — trimming straight across rather than in a curved fashion that might encourage lateral nail spicule formation — can reduce mechanical irritation within the groove. Attention to footwear is equally important. Patients should be counselled to wear shoes with adequate toe box depth and width, ensuring that no undue pressure is applied to the nail borders during ambulation. Orthotic devices, toe props, or silicone nail sulcus protectors may be used to redistribute pressure away from the affected grooves, providing both symptomatic relief and a prophylactic benefit.

Advanced Conservative and Adjunctive Therapies

Where standard debridement and topical therapy are insufficient, several more advanced conservative interventions may be considered. Nail bracing, a technique more commonly associated with the management of involuted nails, has been applied with some success in onychophosis by reducing the transverse curvature of the nail plate and thereby alleviating pressure on the lateral sulci. Adhesive brace systems are bonded across the nail surface and gradually flatten the nail’s curvature over several weeks to months. While evidence for their use specifically in onychophosis is limited compared to ingrown nail conditions, the mechanical rationale is sound and the intervention is minimally invasive.

Padding and strapping techniques can also offer temporary but meaningful relief. Felt or foam padding placed adjacent to the nail groove deflects external pressure, while adhesive strapping of the digit can help stabilise soft tissue and reduce shear forces during weight-bearing activities. These methods are particularly valuable as interim measures while longer-term orthopaedic or footwear modifications are implemented.

Surgical and Procedural Interventions

In cases where conservative management fails to provide lasting relief, or where the structural anatomy of the toe perpetuates recurrent onychophosis, surgical options may be warranted. A partial nail avulsion — the removal of the affected lateral strip of nail — can be performed under local anaesthesia to eliminate the nail edge that contributes to sulcus pressure. This procedure is often combined with phenolisation of the nail matrix, in which phenol is applied to the avulsed nail matrix to permanently ablate that portion and prevent regrowth of the offending nail border. This combined partial nail avulsion and phenolisation approach carries a high success rate and low recurrence when performed correctly, making it a reliable option for patients who have not responded adequately to conservative care.

In patients with significant bony deformity contributing to recurrent onychophosis — such as prominent condyles of the distal phalanx or pronounced digital contractures — referral for orthopaedic or podiatric surgical assessment may be appropriate. Procedures such as digital arthroplasty or condylectomy can address the underlying structural causes, potentially offering a more definitive resolution.

Special Considerations in High-Risk Populations

Management of onychophosis in patients with diabetes mellitus, peripheral arterial disease, or immunosuppression requires particular care. In these populations, even minor trauma to the periungual tissue carries heightened risk of infection, ulceration, or impaired wound healing. Debridement should be performed with great caution, using sterile instruments and minimal tissue disruption. Phenolisation is relatively contraindicated in the presence of significant ischaemia, as wound healing may be compromised. Regular podiatric monitoring, appropriate vascular assessment, and multidisciplinary collaboration are essential components of care in these individuals.

Final Word

Onychophosis, while not life-threatening in the majority of patients, can significantly impair quality of life through chronic pain, restricted mobility, and susceptibility to secondary infection. A thorough clinical assessment, tailored to the individual’s anatomy, lifestyle, footwear habits, and comorbidities, underpins effective treatment. Conservative debridement supported by keratolytic agents, footwear modification, and patient education remains the mainstay of management. Where these measures are insufficient, surgical nail procedures or structural corrections offer durable solutions. As with many podiatric conditions, prevention — through appropriate footwear, regular professional nail care, and prompt attention to early symptoms — remains the most powerful tool available.

Onychomycosis — fungal infection of the nail — is one of the most prevalent dermatological conditions encountered in podiatric practice, accounting for approximately 50% of all nail disorders. It is caused primarily by dermatophytes, most commonly Trichophyton rubrum and Trichophyton mentagrophytes, though non-dermatophyte moulds and Candida species are increasingly recognised as causative organisms, particularly in immunocompromised individuals. The condition disproportionately affects the toenails over the fingernails, and its prevalence rises markedly with age, peripheral vascular disease, diabetes mellitus, and immunosuppression. Despite being perceived by some as a cosmetic nuisance, onychomycosis carries significant clinical implications including pain, difficulty ambulating, secondary bacterial infection, and considerable psychological distress. Effective management therefore demands a thorough, evidence-based approach.

Diagnosis Before Treatment

Accurate diagnosis is the essential prerequisite to any treatment programme. Clinical presentation alone — thickened, discoloured, dystrophic nails — is insufficient to confirm onychomycosis, as similar appearances can result from psoriasis, trauma, lichen planus, and other non-fungal conditions. Mycological confirmation via nail clippings sent for microscopy and culture remains the gold standard, with a sensitivity improved further by polymerase chain reaction (PCR) testing where available. Commencing antifungal therapy without laboratory confirmation risks not only treatment failure but unnecessary systemic drug exposure and cost.

Topical Antifungal Therapy

For mild to moderate onychomycosis — particularly distal and lateral subungual onychomycosis with less than 50% nail plate involvement and no matrix involvement — topical antifungal agents represent a reasonable first-line option. Amorolfine 5% nail lacquer, applied weekly, and ciclopirox 8% nail lacquer, applied daily, are the most widely used preparations. These agents penetrate the nail plate and exert their fungicidal activity directly at the site of infection, avoiding systemic side effects.

However, topical monotherapy has significant limitations. Penetration through the nail plate is inherently difficult, and cure rates with topical agents alone are modest — typically ranging from 5–15% mycological cure at 48 weeks for amorolfine monotherapy in distal subungual onychomycosis. Newer topical agents, including efinaconazole 10% solution and tavaborole 5% solution, demonstrate superior penetration profiles and have shown improved mycological cure rates in clinical trials, reaching 53% and 31% respectively in pivotal studies. These agents represent an advance in topical therapy, particularly for patients in whom systemic treatment is contraindicated.

Topical treatment is most effective when combined with nail debridement — the mechanical reduction of nail thickness — which reduces the fungal burden and improves drug penetration. Podiatrists routinely perform debridement as an adjunct to both topical and systemic treatment.

Systemic Antifungal Therapy

For moderate to severe onychomycosis, matrix involvement, or failure of topical therapy, systemic antifungal agents are the treatment of choice and offer substantially higher cure rates. Two oral agents dominate current practice: terbinafine and the triazole antifungals, principally itraconazole.

Terbinafine, an allylamine that inhibits squalene epoxidase and thus ergosterol synthesis, is considered the gold standard for dermatophyte onychomycosis. A continuous 12-week course for toenail infection achieves mycological cure rates of approximately 70–80%, with complete cure rates (mycological plus clinical) of around 35–50%. Its fungicidal rather than fungistatic mode of action and its high nail keratin affinity contribute to its efficacy. Terbinafine is generally well tolerated, though clinicians must remain alert to rare but serious adverse effects including hepatotoxicity and severe cutaneous reactions such as Stevens-Johnson syndrome. Baseline liver function testing is recommended in those with pre-existing liver disease.

Itraconazole, a triazole that inhibits cytochrome P450-dependent lanosterol 14?-demethylase, may be administered continuously (200 mg daily for 12 weeks) or via pulse dosing (400 mg daily for one week per month, for three pulses). Pulse therapy reduces drug accumulation and cost while retaining acceptable efficacy, with mycological cure rates of approximately 54–63% for toenail infection. Itraconazole has a broader spectrum of activity than terbinafine, making it preferable for non-dermatophyte and Candida-associated infections. Its significant cytochrome P450 3A4 inhibition creates numerous drug interactions, and its negative inotropic properties necessitate caution in patients with cardiac failure.

Fluconazole, administered weekly at 150–300 mg, represents an alternative for patients intolerant of or contraindicated to first-line agents, though evidence for its use in toenail onychomycosis is less robust.

Laser and Device-Based Therapies

Over the past decade, laser therapy has attracted considerable attention as a non-pharmacological treatment option. Nd:YAG lasers operating at 1064 nm, as well as diode and fractional CO2 lasers, have been investigated. The proposed mechanism involves selective photothermal destruction of fungal organisms within the nail. While short-term mycological improvement has been reported, systematic reviews have found the evidence for laser therapy to be of generally low quality, with heterogeneous methodologies and high recurrence rates. Laser treatment is not currently recommended as a primary therapy by major dermatological or podiatric guidelines, though it may have a role as an adjunct or in patients unable to tolerate pharmacological treatment.

Photodynamic therapy (PDT), using photosensitising agents activated by visible light, has also been explored with some promise, particularly for milder cases, but similarly awaits more robust evidence before entering mainstream practice.

Surgical and Mechanical Interventions

Surgical nail avulsion — partial or complete removal of the nail plate — is occasionally employed, particularly when there is marked thickening preventing adequate drug penetration, or in the context of painful subungual hyperkeratosis. Chemical avulsion using 40% urea preparations offers a less invasive alternative, softening and dissolving the nail plate over several weeks to facilitate drug delivery and reduce fungal burden.

Permanent nail ablation via matricectomy — chemical (phenol), surgical, or laser — may be considered in refractory cases or where quality of life is severely impacted by recurrent infection, accepting the consequence of permanent nail loss.

Recurrence and Prevention

Recurrence following successful treatment is a major challenge, affecting up to 50% of patients within five years. Contributing factors include re-infection from environmental reservoirs (shoes, socks, communal areas), concurrent tinea pedis, and host susceptibility factors. Long-term management must therefore incorporate prophylactic measures: antifungal foot powders, replacement of contaminated footwear, treatment of concurrent tinea pedis, and patient education on hygiene practices in communal bathing environments. In high-risk individuals — particularly those with diabetes or peripheral vascular disease — regular podiatric monitoring and preventive nail care are essential components of ongoing management.

The treatment of onychomycosis in the foot requires a patient-centred, stepwise approach guided by accurate diagnosis, severity assessment, and individual risk factors. While topical agents suffice for mild disease, systemic antifungals — principally terbinafine — remain the cornerstone of treatment for most cases. Mechanical debridement, adjunctive topical therapy, and preventive education are integral to achieving durable cure. Emerging technologies such as novel topical agents and laser therapy broaden the therapeutic landscape, though further evidence is needed to establish their definitive role. Given its high prevalence, tendency to recur, and impact on quality of life, onychomycosis warrants the careful, sustained clinical attention that effective podiatric practice affords.

Diabetic peripheral neuropathy (DPN) is one of the most prevalent and debilitating complications of diabetes mellitus, affecting up to 50% of people living with the condition over their lifetime. It is a major driver of foot ulceration, lower limb amputation, and cardiovascular autonomic dysfunction, carrying significant burdens for both patients and healthcare systems. Early, accurate detection is therefore critical — yet standard neurological assessments can be time-consuming, require specialist equipment, and are poorly suited to routine clinical settings. Into this gap has stepped the Neuropad, a simple, point-of-care indicator test that detects sudomotor (sweat gland) dysfunction as a proxy marker for small autonomic nerve fibre damage. Understanding how it works, what the evidence says, and where it fits in clinical practice is essential for clinicians managing diabetes.

How Neuropad Works

Neuropad is a small adhesive plaster developed by TRIGOcare International and designed for application to the plantar (sole) surface of the foot. The pad contains anhydrous cobalt (II) chloride — a blue compound that undergoes a well-characterised colour change when it absorbs water. When applied to the skin for ten minutes, a normal sudomotor response causes the pad to turn from blue to pink, reflecting adequate moisture from sweat glands. An abnormal or incomplete colour change — the pad remaining blue or turning only partially pink — indicates reduced or absent sweating, which is a hallmark of small autonomic C-fibre dysfunction.

The test is patented as a ten-minute screening tool for early detection of diabetic foot syndrome. It is non-invasive, painless, and requires no specialised equipment beyond the plaster itself, making it readily deployable in primary care, diabetes clinics, or even as a patient self-test at home. At a list price of approximately £7.28 per test (as assessed by NICE), it is substantially more affordable than nerve conduction studies or skin biopsy.

The Scientific Basis: Sudomotor Dysfunction in Neuropathy

Sweating in the feet is regulated by postganglionic cholinergic sympathetic nerve fibres — small, unmyelinated C-fibres that are among the earliest structures damaged in diabetic neuropathy. Sudomotor dysfunction therefore represents an early and sensitive marker of neuropathic change, often preceding clinical symptoms and detectable deficits in large-fibre tests such as vibration perception or nerve conduction velocity.

This biological rationale lends Neuropad particular relevance to the detection of small-fibre neuropathy — a form of DPN that traditional assessments poorly capture. Established tools such as the Neuropathy Disability Score (NDS) and nerve conduction studies (NCS) predominantly assess large myelinated fibres, and can miss early small-fibre involvement entirely.

Diagnostic Performance

The evidence base for Neuropad has grown substantially over the past two decades, with numerous clinical studies examining its sensitivity, specificity, and correlation with established neuropathy markers.

A landmark 2008 study by Quattrini et al., published in Diabetologia, evaluated 57 diabetic patients using Neuropad alongside quantitative sensory testing, autonomic function assessments, and intra-epidermal nerve fibre density from skin biopsy. The results demonstrated meaningful correlations between Neuropad responses and the NDS, neuropathic symptom scores, cold detection thresholds, and deep-breathing heart rate variability — reflecting both somatic and autonomic neuropathic involvement.

Subsequent studies have further characterised its performance profile. Across assessments against large-fibre neuropathy markers — such as the NDS and peroneal motor nerve conduction velocity — Neuropad demonstrates high sensitivity (typically 80–95%) but moderate specificity (50–70%). This pattern makes it well-suited as a screening tool: a normal result reliably reduces the likelihood of clinically significant neuropathy, but an abnormal result warrants further investigation.

Importantly, diagnostic accuracy is meaningfully improved when Neuropad is assessed against small-fibre measures. A 2014 study by Ponirakis and colleagues found that, compared with corneal nerve fibre length — a sensitive marker of small-fibre damage assessed by corneal confocal microscopy — Neuropad achieved a sensitivity of 83% and specificity of 80%, with an area under the ROC curve (AUC) of 85%. This outperformed its performance against both the NDS (AUC 66%) and peroneal motor nerve conduction velocity (AUC 70%), underscoring the test’s specific utility for small C-fibre assessment.

An important refinement involves moving beyond simple binary (pink/blue) interpretation to quantifying the rate of colour change. A study examining automated image analysis (Sudometrics) demonstrated that continuous colour-change output substantially improved diagnostic accuracy, achieving high sensitivity and specificity for autonomic dysfunction (91% and 83% respectively) and small-fibre neuropathy (88% and 78%), compared with the weaker specificity of the categorical reading alone.

Research has also established Neuropad’s reproducibility. A study in 142 type 2 diabetic patients found a highly significant correlation (r = 0.91) between repeat measurements of time to complete colour change, indicating strong test-retest reliability.

Autonomic Neuropathy and Cardiovascular Risk

Beyond peripheral neuropathy, Neuropad has been evaluated as a tool for detecting cardiovascular autonomic neuropathy (CAN) — a potentially life-threatening condition associated with silent myocardial ischaemia, arrhythmia, and increased mortality. Time to complete colour change correlates significantly with the Valsalva ratio, a standard autonomic function test, as well as with symptoms of DPN and postural hypotension. A cut-off of fifteen minutes for complete colour change has been identified as an optimal threshold, improving specificity for both CAN and DPN without compromising sensitivity.

Given that CAN often goes undetected until advanced stages, the ability of a simple plaster to prompt further autonomic evaluation is clinically meaningful.

Limitations and Clinical Considerations

Neuropad is not without limitations. Its moderate specificity, particularly against large-fibre assessments, means a positive result should not be used in isolation for diagnosis. Environmental factors — ambient temperature, skin moisture, and humidity — may influence the rate and completeness of colour change, adding variability to qualitative readings. Age, BMI, renal function, and alcohol use have also been identified as potential confounders of sudomotor function independent of glycaemic status.

In elderly populations with diabetes or pre-diabetes, the KORA F4 survey found reasonable sensitivity but low specificity for polyneuropathy diagnosis, with a positive predictive value as low as 33.6%. This supports positioning Neuropad as a triage or exclusion test rather than a standalone diagnostic.

NICE evaluated Neuropad under its Medical Technologies Guidance programme (MTG38, 2018), recommending it as an option for detecting early DPN, particularly in settings where more specialised testing is unavailable. The guidance acknowledged its ease of use and potential value in identifying patients who require further assessment.

Conclusion

The Neuropad test occupies a valuable niche in the clinical assessment of diabetic neuropathy. By providing a simple, inexpensive, and non-invasive window into sudomotor and small C-fibre function, it enables early detection of neuropathic changes that traditional large-fibre assessments routinely miss. Its high sensitivity makes it particularly effective as a screening and exclusion tool, and its performance improves markedly when interpreted quantitatively or benchmarked against small-fibre measures. While it should not replace comprehensive neurological evaluation, Neuropad represents a practical and evidence-based addition to the diabetic foot assessment toolkit — one that can meaningfully support earlier intervention and reduce the risk of serious complications.

Onychomycosis, commonly known as fungal nail infection, is one of the most prevalent dermatological conditions affecting the toenails. It accounts for approximately 50% of all nail disorders and affects an estimated 10% of the global population, with incidence rising sharply with age. Caused primarily by dermatophytes — particularly Trichophyton rubrum and Trichophyton mentagrophytes — as well as non-dermatophyte moulds and yeasts, the infection penetrates the nail plate and nail bed, producing characteristic features including thickening, discolouration, brittleness, and subungual debris. While traditionally managed with oral antifungal agents or topical therapies, laser treatment has emerged over the past two decades as a compelling alternative, offering a non-systemic and increasingly well-tolerated option for patients.

The Limitations of Conventional Therapy

To appreciate why laser therapy has gained traction, one must first understand the shortcomings of existing treatments. Oral antifungal agents such as terbinafine and itraconazole remain the gold standard, achieving mycological cure rates of 70–80% in clinical trials. However, they carry significant concerns: hepatotoxicity risk, drug–drug interactions, and the need for prolonged courses of treatment — often 12 weeks or more. These limitations are particularly problematic for elderly patients, who bear the greatest burden of onychomycosis and who frequently take multiple concurrent medications. Topical antifungal agents, including amorolfine lacquer and ciclopirox, circumvent systemic side effects but suffer from poor nail plate penetration, resulting in clinical cure rates typically below 10–15%. These inadequacies created the clinical impetus for laser-based alternatives.

Mechanisms of Laser Action

Laser therapy for onychomycosis operates on the principle of selective photothermolysis and direct thermal damage to fungal organisms. The nail plate and subungual space are heated to temperatures sufficient to denature fungal cell proteins and disrupt membrane integrity, ideally without causing collateral damage to surrounding host tissue. Several laser systems have been investigated, the most commonly studied being the Nd:YAG (neodymium-doped yttrium aluminium garnet) laser operating at 1064 nm, the diode laser at 870/930 nm, the carbon dioxide (CO?) laser at 10,600 nm, and more recently, fractional and photodynamic light-based systems.

The 1064 nm Nd:YAG laser is the most widely adopted platform. Its longer wavelength allows deeper tissue penetration, reaching the nail bed where fungal colonies reside, while melanin in surrounding tissue absorbs relatively less energy at this wavelength, conferring a degree of selectivity. During a typical session, the laser is passed repeatedly across the nail surface in a grid or circular pattern, raising intraungual temperature to approximately 45–60°C — a threshold associated with fungal death — while patient discomfort is managed through appropriate fluence settings and cooling intervals.

Clinical Evidence

The clinical evidence base for laser treatment has expanded considerably, though it remains heterogeneous and methodologically variable. A number of randomised controlled trials and prospective studies have demonstrated statistically significant improvements in mycological cure — defined as negative fungal culture and microscopy — following laser treatment. Cure rates in published trials vary widely, from as low as 12% to as high as 84%, reflecting differences in laser type, treatment parameters, number of sessions, patient selection, and outcome assessment timing.

Studies using the Nd:YAG laser have reported mycological cure rates of approximately 30–60% following three to six treatment sessions spaced four to eight weeks apart. Clinical improvement in nail appearance — reduced discolouration, decreased subungual hyperkeratosis — is often observed even in the absence of full mycological cure, which holds particular value for patients whose primary concern is cosmetic. Combination approaches, pairing laser treatment with topical antifungals or nail debridement, have shown promise in improving overall outcomes, suggesting that monotherapy laser treatment may not be sufficient for severe or long-standing infections.

A notable challenge in evaluating laser therapy is the slow growth of the toenail: the great toenail takes approximately 12–18 months to grow out fully. This means that clinical cure, defined as the presence of a completely normal nail, may not be assessable until well after the treatment course concludes. Many studies with shorter follow-up periods therefore capture only interim outcomes, potentially overestimating or underestimating true efficacy.

Safety Profile and Patient Tolerability

One of the most compelling attributes of laser therapy is its favourable safety profile. Unlike oral antifungals, laser treatment carries no systemic toxicity, requires no blood monitoring, and produces no drug interactions. It is therefore particularly suitable for patients with hepatic impairment, those on polypharmacy regimens, and individuals who have failed or cannot tolerate systemic therapy. Adverse effects are generally mild and transient, including localised warmth, erythema, and occasional post-procedure tenderness. Scarring and permanent nail damage are rare when appropriate protocols are followed.

The procedure is typically performed in an outpatient or podiatric clinic setting, requiring no anaesthesia, though some patients — particularly those with thicker, more dystrophic nails — experience discomfort during treatment. Nail debridement prior to laser application is commonly performed to reduce nail thickness and improve laser penetration, enhancing treatment efficacy.

Current Position in Clinical Practice

Despite its growing use, laser therapy for onychomycosis is not yet universally recognised as a first-line treatment. Regulatory approval varies by jurisdiction; in many countries, laser devices are cleared for use in onychomycosis but without the level of clinical evidence that would rank them alongside established pharmacological agents in major treatment guidelines. The cost of laser treatment — which is rarely subsidised by public health systems — remains a barrier for many patients, particularly given that multiple sessions are required.

Podiatrists and dermatologists increasingly integrate laser therapy within a broader management framework: it may be offered as an alternative for patients who cannot tolerate oral agents, as an adjunct to topical therapy in moderate disease, or as a standalone option for mild to moderate infections. Patient counselling regarding realistic expectations is essential; complete cure is not guaranteed, recurrence rates are not negligible, and the timeline to a visibly normal nail is measured in months to years.

Laser treatment represents a meaningful advance in the management of onychomycosis of the foot. Grounded in sound biophysical principles and supported by a growing body of clinical evidence, it offers an efficacious, safe, and systemically inert option in a therapeutic landscape historically dominated by drugs with significant limitations. As laser technologies evolve, treatment protocols are refined, and longer-term outcome data accumulate, the role of laser therapy is likely to consolidate further. For now, it occupies an important and expanding niche — particularly for the elderly, the medically complex, and those who have exhausted other options — signalling a genuine shift in how clinicians approach this stubborn and frequently undertreated condition.